INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute (RZLT)

Faruqi & Faruqi, LLP, a prominent national securities law firm, has initiated an investigation concerning potential claims on behalf of investors in Rezolute, Inc. (NASDAQ: RZLT). This inquiry comes in response to significant losses suffered by investors following a drastic decline in the company's stock price, particularly after a disappointing outcome from a key clinical trial. On December 11, 2025, shares of Rezolute plummeted nearly 85-90%, crashing from approximately $10.94 to an intraday low of around $0.90. This collapse was triggered by inadequate topline results from the Phase 3 sunRIZE clinical trial of ersodetug, Rezolute's lead drug for congenital hyperinsulinism, which failed to meet its primary and secondary endpoints.

As a result of these failed outcomes, trading on the stock was suspended under Nasdaq's volatility regulations, prompting Faruqi & Faruqi to encourage affected investors to reach out for discussions about their legal rights. The firm's partner, James (Josh) Wilson, is urging individuals who experienced substantial losses in their investments during this tumultuous period to contact him directly at designated phone numbers. This investigative effort builds on Faruqi & Faruqi's history of successfully recovering hundreds of millions for investors since its establishment in 1995.

For those interested in learning more about the investigation or seeking potential legal recourse, they are invited to visit the firm's website or contact Wilson. The firm ensures that all communications will be confidential and welcomes the opportunity to assess individual cases. As the situation unfolds, further updates will be provided through their social media channels.

The recent investigation notice by Faruqi & Faruqi, LLP regarding Rezolute, Inc. (NASDAQ: RZLT) serves as a critical red flag for investors. Following a dramatic decline in the company's stock price—plummeting from approximately $10.94 to an intraday low near $0.90 after disappointing results from its Phase 3 clinical trial for ersodetug—investors are understandably concerned. The trial’s failure to meet primary and secondary endpoints raises significant questions about the viability of Rezolute's lead drug candidate and the company's future prospects.

Given the substantial loss in market capitalization and ongoing investigation into potential implications of this failure, investors should approach RZLT with caution. Those who have suffered significant losses may see this as an opportunity for legal recourse, but it is essential to weigh the potential benefits against the inherent risks of litigation. Engaging with a firm like Faruqi & Faruqi could provide insights and options for recovery; however, investors must also consider the uncertainty surrounding the effectiveness of these actions.

From a market perspective, RZLT's sharp decline emphasizes the volatility typical of biopharmaceutical stocks, especially those at developmental stages. Investors need to conduct thorough due diligence, considering not only the clinical outlook but also the overall financial health of the company. Monitoring Rezolute's subsequent communications, potential restructuring, or new strategic partnerships will be vital in assessing recovery capabilities.

In conclusion, while Rezolute may offer speculative opportunities for some investors, a prudent approach requires vigilance and a critical assessment of associated risks. Those with current positions may want to consult with professionals to navigate potential courses of action effectively.